Cue Biopharma, Inc.
CUE
$29.47
$0.210.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 121.28% | 12.19% | 30.80% | -29.08% | -9.65% |
| Total Depreciation and Amortization | 328.90% | -188.65% | 1,461.39% | -95.08% | 245.25% |
| Total Amortization of Deferred Charges | -10.00% | 11.11% | 0.00% | 0.00% | -10.00% |
| Total Other Non-Cash Items | -140.89% | 565.83% | -76.06% | 411.29% | -118.15% |
| Change in Net Operating Assets | -23.53% | -221.95% | 62.61% | 302.44% | 29.17% |
| Cash from Operations | 88.08% | -164.25% | 58.21% | 9.48% | -19.94% |
| Capital Expenditure | -- | 100.00% | 82.00% | -7,400.00% | -300.00% |
| Sale of Property, Plant, and Equipment | 0.00% | -- | -- | -- | -98.97% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 203.12% | -- | -- | -- | -- |
| Cash from Investing | 203.72% | -24,966.67% | 82.00% | -14,900.00% | -101.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -50.00% | 0.00% | 0.00% | -0.10% | 0.10% |
| Issuance of Common Stock | 998.10% | -94.67% | -- | -- | -99.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 949,100.00% | -99.99% | 1,879.80% | -7.30% | -109.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 197.75% | -210.00% | 254.00% | 6.42% | -516.43% |